Literature DB >> 35933454

Design and synthesis of novel quinazolinyl-bisspirooxindoles as potent anti-tubercular agents: an ultrasound-promoted methodology.

Bhargava Sai Allaka1, Srinivas Basavoju2, Estharla Madhu Rekha3, Dharmarajan Sriram3, Gamidi Rama Krishna4.   

Abstract

The essential need for the potent anti-tubercular (anti-TB) agents with high selectivity and safety profile prompted us to synthesize a new series of quinazolinyl-bisspirooxindoles. The title compounds were synthesized by one-pot multicomponent [3 + 2] cycloaddition reaction under ultrasonication. Further, in vitro anti-TB activity was evaluated against Mycobacterium tuberculosis H37Rv. Among the screened compounds, two compounds (4q and 4x) showed potent activity with MIC value 1.56 µg/mL and four compounds exhibited significant activity (MIC = 3.125 µg/mL), and also cytotoxicity studies against RAW 264.7 cell lines reveal that most active compounds were less toxic to humans. In addition, in order to demonstrate the inhibitory properties, molecular docking studies were carried out and the results showed that the target compounds have good binding energy and better binding affinity within the active pocket, thus these compounds may consider to be as potent inhibitors toward selective targets.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Anti-tubercular activity; Bisspirooxindoles; Cytotoxicity screening; Molecular docking studies; Ultrasonication

Year:  2022        PMID: 35933454     DOI: 10.1007/s11030-022-10500-x

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   3.364


  27 in total

1.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

Review 2.  An overview of spirooxindole as a promising scaffold for novel drug discovery.

Authors:  Li-Ming Zhou; Ren-Yu Qu; Guang-Fu Yang
Journal:  Expert Opin Drug Discov       Date:  2020-02-28       Impact factor: 6.098

Review 3.  Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance.

Authors:  Ilse Du Preez; Du Toit Loots
Journal:  Drug Metab Rev       Date:  2019-01-07       Impact factor: 4.518

Review 4.  Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.

Authors:  K M De Cock; R E Chaisson
Journal:  Int J Tuberc Lung Dis       Date:  1999-06       Impact factor: 2.373

Review 5.  Anticancer potential of spirocompounds in medicinal chemistry: A pentennial expedition.

Authors:  Darshana Bora; Anjali Kaushal; Nagula Shankaraiah
Journal:  Eur J Med Chem       Date:  2021-02-06       Impact factor: 6.514

Review 6.  Drug discovery using spirooxindole cores: Success and Challenges [corrected].

Authors:  Bin Yu; Zhiqiang Yu; Ping-Ping Qi; De-Quan Yu; Hong-Min Liu
Journal:  Eur J Med Chem       Date:  2015-03-12       Impact factor: 6.514

Review 7.  Multidrug resistant tuberculosis - Diagnostic challenges and its conquering by nanotechnology approach - An overview.

Authors:  Lakshmipathy Muthukrishnan
Journal:  Chem Biol Interact       Date:  2021-01-26       Impact factor: 5.192

Review 8.  Tuberculosis: a disease without boundaries.

Authors:  Nicole Fogel
Journal:  Tuberculosis (Edinb)       Date:  2015-06-25       Impact factor: 3.131

Review 9.  Tuberculosis chemotherapy: recent developments and future perspectives.

Authors:  Veemal Bhowruth; Lynn G Dover; Gurdyal S Besra
Journal:  Prog Med Chem       Date:  2007

10.  Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity.

Authors:  Sara T Al-Rashood; Ahmed R Hamed; Ghada S Hassan; Hamad M Alkahtani; Abdulrahman A Almehizia; Amal Alharbi; Mohammad M Al-Sanea; Wagdy M Eldehna
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.